U.S. Ranks Last Among Wealthy Nations in Health Care Access

Share this content:
U.S. Ranks Last Among Wealthy Nations in Health Care Access
U.S. Ranks Last Among Wealthy Nations in Health Care Access

(HealthDay News) -- The U.S. health care system ranks last compared to other industrialized nations when it comes to affordability and patient access, according to a new survey published in the Oct. 23 issue of the New England Journal of Medicine.

The 2013 survey of the American health care landscape was conducted by the Commonwealth Fund and written by Karen Davis, Ph.D., and Jeromie Ballreich, M.H.S., of the Johns Hopkins Bloomberg School of Public Health in Baltimore, just prior to the full implementation of the Obama administration's Affordable Care Act (ACA). The survey included Canada, Australia, France, Germany, the Netherlands, New Zealand, Norway, Sweden, Switzerland, the United Kingdom, and the United States.

Of these, the United Kingdom, France, Germany, Norway, Sweden, and Switzerland ranked highest in terms of access to care irrespective of personal wealth. The survey concluded that at least three in 10 Americans say that money is a barrier to getting medical attention. This compared with roughly one in 10 among residents of the other countries polled.

"This was before the major insurance expansions [due to the ACA] went into effect in the U.S.," David Squires, a senior researcher with the Commonwealth Fund in New York City, told HealthDay. "So the millions who have since gotten insurance through exchanges or Medicare are not [reflected] in this survey, which means I think one way to read these findings is as a benchmark. The survey lays down where we were. And now future surveys will be able to measure the impact of the ACA."

Full Article
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

FDA OKs Doptelet for Liver Dz Patients Undergoing ...

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure

Slower Decline in Lung Function With Anthocyanin Intake

Slower Decline in Lung Function With Anthocyanin Intake

Slower annual rates of decline in FEV1 and FVC for those in highest quartile of anthocyanin intake

Bioengineering Feasible for Airway Reconstruction

Bioengineering Feasible for Airway Reconstruction

Bioengineered tracheal and bronchial reconstruction reported using stented aortic matrices

is free, fast, and customized just for you!

Already a member?

Sign In Now »